The major objective of the, Duke Skin Disease Research Core Center (Duke SDRC) is to provide SDRC members and others access to the technologies and resources needed to facilitate biological studies at the gene, cellular, tissue, and animal levels. The Administrative Core will be responsible for oversight of the core services and overall center operations. Dr. Russell Hall will have primary responsibility for supervising and coordinating the day to day operations of the SDRC. He will be assisted by the Associate Director, the SDRC administrator, and the leaders of the Research Cores. The governance of the SDRC will be provided by an Executive Committee consisting of the Director, Associate Director, Research Core Directors, and the Director of the Enrichment Program; input will be obtained quarterly from an internal advisory committee on scientific direction, optimal integration of the Center with existing institutional resources, adequacy and quality of performance in the Research Cores, and overall vision for the Center. The members of the Advisory Committee will be chosen based on their credentials as researchers, specific content expertise for one or more of the Cores, and demonstrated success in leadership programs aimed at translating basic discoveries into clinical practice.
The Specific Aims of the Administrative Core are the following: (1) Provide oversight of the Center's operations, performance, and utilization, including re-allocation of resources as appropriate. (2) Define and implement application process for Center membership based on investigator eligibility, scientific excellence, and relevance to skin biology and/or skin diseases. (3) Assess ongoing suitability and utilization of core services and implement changes as dictated by new technology, demands for new services, economic factors, and/or outcomes. (4) Provide communication infrastructure and promote collaboration between investigators and core to optimize the Center's impact.
The Administrative Core will provide direction and oversight to all elements of the SDRC. This core will ensure that all research cores are providing services appropriately; that the enrichment program is attracting new investigators and enhancing the productivity of all members; that SDRC resources are allocated in a productive and transparent fashion; and that services and progress are evaluated effectively.
| Klann, Tyler S; Crawford, Gregory E; Reddy, Timothy E et al. (2018) Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing. Methods Mol Biol 1767:447-480 |
| Klann, Tyler S; Black, Joshua B; Gersbach, Charles A (2018) CRISPR-based methods for high-throughput annotation of regulatory DNA. Curr Opin Biotechnol 52:32-41 |
| Chen, Yong; Moore, Carlene D; Zhang, Jennifer Y et al. (2017) TRPV4 Moves toward Center-Fold in Rosacea Pathogenesis. J Invest Dermatol 137:801-804 |
| Polstein, Lauren R; Juhas, Mark; Hanna, Gabi et al. (2017) An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis. ACS Synth Biol 6:2003-2013 |
| Suwanpradid, Jutamas; Holcomb, Zachary E; MacLeod, Amanda S (2017) Emerging Skin T-Cell Functions in Response to Environmental Insults. J Invest Dermatol 137:288-294 |
| Liu, Xinjian; Li, Fang; Huang, Qian et al. (2017) Self-inflicted DNA double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell Res 27:764-783 |
| Klann, Tyler S; Black, Joshua B; Chellappan, Malathi et al. (2017) CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol 35:561-568 |
| Zhang, Xiaoling; Luo, Suju; Wu, Joseph et al. (2017) KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage. J Invest Dermatol 137:475-483 |
| Liu, Xinjian; Zhou, Min; Mei, Ling et al. (2016) Key roles of necroptotic factors in promoting tumor growth. Oncotarget 7:22219-33 |
| Jin, Yingai Jane; Wang, Sally; Cho, Joshua et al. (2016) Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors. JCI Insight 1: |
Showing the most recent 10 out of 26 publications
